Stereotactic radiosurgery for acoustic neuromas: What happens long term?
Date
2012
Authors
Roos, D.
Potter, A.
Brophy, B.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
International Journal of Radiation: Oncology - Biology - Physics, 2012; 82(4):1352-1355
Statement of Responsibility
Daniel E. Roos, Andrew E. Potter, Brian P. Brophy
Conference Name
Abstract
<h4>Purpose</h4>To determine the clinical outcomes for acoustic neuroma treated with low-dose linear accelerator stereotactic radiosurgery (SRS) >10 years earlier at the Royal Adelaide Hospital using data collected prospectively at a dedicated SRS clinic.<h4>Methods and materials</h4>Between November 1993 and December 2000, 51 patients underwent SRS for acoustic neuroma. For the 44 patients with primary SRS for sporadic (unilateral) lesions, the median age was 63 years, the median of the maximal tumor diameter was 21 mm (range, 11-34), and the marginal dose was 14 Gy for the first 4 patients and 12 Gy for the other 40.<h4>Results</h4>The crude tumor control rate was 97.7% (1 patient required salvage surgery for progression at 9.75 years). Only 8 (29%) of 28 patients ultimately retained useful hearing (interaural pure tone average ≤50 dB). Also, although the Kaplan-Meier estimated rate of hearing preservation at 5 years was 57% (95% confidence interval, 38-74%), this decreased to 24% (95% confidence interval, 11-44%) at 10 years. New or worsened V and VII cranial neuropathy occurred in 11% and 2% of patients, respectively; all cases were transient. No case of radiation oncogenesis developed.<h4>Conclusions</h4>The long-term follow-up data of low-dose (12-14 Gy) linear accelerator SRS for acoustic neuroma have confirmed excellent tumor control and acceptable cranial neuropathy rates but a continual decrease in hearing preservation out to ≥10 years.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Crown copyright © 2012 Published by Elsevier Inc. All rights reserved.